EUVIMEDEUVIMED entdecken
Crossref

BOIN12 ‐ PFS : A Bayesian Optimal Interval Phase I / II Design Incorporating Progression‐Free Survival Endpoint

Yusuke Tanaka iD, Kentaro Takeda iD, Ryo Kitabayashi iD, Hiroyuki Sato iD, Akihiro Hirakawa iD

Pharmaceutical Statistics · 2026

DOI: 10.1002/pst.70133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Yusuke Tanaka und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Research Design, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Modern oncology drug development is increasingly focused on identifying the optimal biological dose (OBD) rather than just the maximum tolerated dose (MTD). Early‐phase oncology trials have conventionally relied on short‐term endpoints, such as overall response rate (ORR), to evaluate efficacy. However, there is a growing perception that incorporating longer‐term endpoints, such as progression‐free survival (PFS), into early‐phase dose‐finding trials can provide more informative guidance for dose optimization. This study proposes a new design, BOIN12‐PFS, to identify the optimal dose based on PFS, short‐term efficacy, and toxicity. As an extension of the BOIN12 design, BOIN12‐PFS is expected to be comparatively straightforward to implement in clinical oncology dose‐finding trials. Simulation studies demonstrate that the BOIN12‐PFS design offers advantages over existing designs in terms of the probability of selecting the OBD, the average number of patients allocated to the OBD, reducing overdosing, and requiring a smaller total sample size across various realistic settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsResearch DesignClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicNeoplasmsHumansBayes TheoremMaximum Tolerated DoseDose-Response Relationship, DrugProgression-Free SurvivalComputer SimulationEndpoint DeterminationSample Size

Stichwörter der Autor:innen

dose optimizationmodel‐assisted designprogression‐free survival

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.
  • Quantitative Science and Evidence Generation, Astellas Pharma Inc., Tokyo, Japan.
  • Quantitative Science and Evidence Generation, Astellas Pharma Global Development Inc., Northbrook, Illinois, USA.

ORCID-Profile: Yusuke Tanaka, Kentaro Takeda, Ryo Kitabayashi, Hiroyuki Sato, Akihiro Hirakawa

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development

Zitieren

APA

Tanaka, Y., Takeda, K., Kitabayashi, R., Sato, H., & Hirakawa, A. (2026). BOIN12 ‐ PFS : A Bayesian Optimal Interval Phase I / II Design Incorporating Progression‐Free Survival Endpoint. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70133

Vancouver

Tanaka Y, Takeda K, Kitabayashi R, Sato H, Hirakawa A. BOIN12 ‐ PFS : A Bayesian Optimal Interval Phase I / II Design Incorporating Progression‐Free Survival Endpoint. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70133

BibTeX
@article{Tanaka2026,
  author = {Tanaka, Yusuke and Takeda, Kentaro and Kitabayashi, Ryo and Sato, Hiroyuki and Hirakawa, Akihiro},
  title = {BOIN12 ‐ PFS : A Bayesian Optimal Interval Phase I / II Design Incorporating Progression‐Free Survival Endpoint},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  doi = {10.1002/pst.70133}
}
Kostenlos starten →